Our one-day Certified COSHH for Laboratories and Research course is suitable for employees of all levels working in the lab environment.
We have designed this course to cover the fundamental requirements of the Control of Substances Hazardous to Health Regulations, providing you with the tools and confidence to identify hazards, assess risk, measure impacts and implement controls in line with best practice.
Detachin™ Cell Detachment Solution from Amsbio provides a superior alternative to Trypsin/EDTA for gentle detachment of adherent cells from in vitro growth vessels.
Highly accomplished senior real estate executive leader and investment professional, Andy Creighton, joins Howard Group
With almost 40m UK users, you can’t afford to ignore the power of LinkedIn to reach, connect and engage with other business users. But constant algorithm changes and more content being shared means keeping up-to-date with best practice and building your visibility on LinkedIn is more challenging than ever.
Join Dan Ince, Managing Director at BrandWorks Social, for a thought-provoking talk on why you need to stand out more than ever on LinkedIn, and practical steps you can take to build visibility without it becoming overwhelming.
LONDON, UK – November 19, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Slingshot Therapeutics Limited (“Slingshot”) and is pleased to announce the placement of Dr. John Isaac as Chief Scientific Officer (CSO). Slingshot’s founding CSO Richard Wooster will now transition to a non-executive role as Scientific Advisor and Board member.
Over four decades since its conception in 1980, Fragment-Based Drug Discovery (FBDD) has emerged as an innovative and efficient approach to modern drug development, showing advantages over traditional high-throughput screening (HTS) methods. By focusing on smaller, simpler molecules, FBDD provides a foundation for developing novel therapeutics, especially for challenging previously “undruggable” targets.
Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.
Cambridge, UK – 19 November 2025 – Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases.
The UK is set to give a unique second life to used nuclear materials. A £9.9m investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP), backed by a further £8.9m from industry, will support a major project to develop cutting-edge new treatments for cancer.
Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create treatments called Targeted Alpha Therapies.
Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership team
· Stephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisation
Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.